MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma

Abstract: In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment decisions remains unclear. In a phase 2 trial, we assessed daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) induction followed by...

Full description

Saved in:
Bibliographic Details
Main Authors: Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry Paul, Fei Guo, Jason M. Grayson, Anna Ivanina-Foureau, Mauricio Pineda-Roman, Cindy Varga, Reed Friend, Christopher J. Ferreri, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B. Anderson, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292400675X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S247395292400675X

Similar Items